bioMérieux announced on October 22, 2026 that the U.S. Food and Drug Administration has granted dual 510(k) clearance and a CLIA waiver to its BIOFIRE SPOTFIRE Vaginitis Panel, a molecular test that returns results in about 20 minutes. The announcement was made from Marcy-l’Étoile, France.
What the panel reports
The panel gives eight results from a single vaginal swab. One is bacterial vaginosis, reported as a binary result. Six are yeast species: Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis and C. dubliniensis. The eighth is the parasite Trichomonas vaginalis.
Bacterial vaginosis is not called from a single organism. According to the company, an algorithm assesses the relative abundance of several bacteria, including Fannyhessea (Atopobium) vaginae, BVAB2, Lactobacillus crispatus, L. gasseri/paragasseri, L. jensenii/mulieris and Sneathia sanguinegens/vaginalis (amnii). These feed the algorithm and are not reported as separate results.
Sample and setting
Each test uses one swab. Both self-collected and clinician-collected vaginal swabs can be used. The CLIA waiver means the test can be run by non-laboratory professionals at the point of care. bioMérieux names family care practices, urgent care and OB/GYN offices as intended settings.
Availability
Commercial availability in the United States is planned for the beginning of 2027, followed by a wider international rollout.
Jennifer Zinn, Executive Vice President, Clinical Operations at bioMérieux, said: “Today, there is a clear and persistent gap in vaginitis diagnostics.”
What the announcement does not include
The press release does not report clinical performance figures such as sensitivity and specificity, and it does not give a formal intended-use statement. Laboratories evaluating the panel will need the FDA decision documents and the instructions for use for those details.
Technical note for laboratories
The panel combines bacterial, yeast and parasite targets in one swab and one run. Whether it changes workflow in a given setting depends on the performance data, instrument availability and reimbursement, none of which were part of the announcement.